Expanding indications of statins; implications of the Heart Protection Study.
The Heart Protection Study is the largest trial of statin therapy conducted to date. It provides important new information on the use of statins in women, the elderly, diabetics and people with low baseline cholesterol pretreatment and those with prior occlusive non-coronary vascular disease. In this report, the paper is discussed with the significance of the results outlined in view of existing evidence from previously published trials. In addition, ongoing trials and future directions are explored.
Salam
Amar M
AM
Department of Cardiology and Cardiovascular Surgery, Hamad Medical Corporation, Doha, Qatar. amaramin@yahoo.com
D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003327:Coronary Disease / Q000150:complications / Q000188:drug therapy / Q000517:prevention & control; D048909:Diabetes Complications; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012737:Sex Factors; D019821:Simvastatin / Q000009:adverse effects / Q000627:therapeutic use*; D020521:Stroke / Q000209:etiology / Q000517:prevention & control
D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D019821:Simvastatin